First patient enrolled in our relieve study!

We are proud to announce that the first patient has been enrolled in our ‘Relieve’ clinical study, marking a significant milestone in our pursuit to enhance the quality of life for Crohn’s disease patients.

Crohn’s disease can lead to nutrient deficiencies and has unpredictable flare-ups and remission periods. During the remission phases, IBS-like symptoms can persist in 50% of patients, for which no satisfactory treatment is available yet. Important to mention here is that these IBS-like symptoms may also manifest in other conditions like e.g. celiac disease, colitis, colorectal cancer, and chronic GI infections.

This Randomized Double-blinded Crossover Trial focuses on investigating the potential of BK003, our chitin-glucan based asset, in alleviating IBS-like symptoms during remission in Crohn’s patients.

The study will be conducted in France and Belgium over 10 weeks, and aims to assess the safety and efficacy of BK003 vs placebo. Primary objectives are SGA scores (Subjective Global Assessment of relief responder rate). Secondary objectives are to assess changes in bowel habits, anxiety and depression, and overall quality of life.

For more details on the Relieve Study visit Clinicaltrials.gov (ID: NCT05780749).

Discover our press release (FR) here